Clinical Trials Browser

Interventional × Has results × Bendamustine Hydrochloride × Clear all

NCT03856216 2026-04-15

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

Phase 2 Terminated

15 enrolled 11 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01886872 2026-04-13

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase 3 Active not recruiting

547 enrolled 19 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01661881 2026-04-08

Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

Phase 2 Active not recruiting

23 enrolled 8 charts

Lymphoma, Mantle-Cell

NCT03623373 2026-03-30

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

Phase 2 Completed

13 enrolled 13 charts

Lymphoma, Mantle-Cell

NCT03336333 2026-03-09

SEQUOIA

Phase 3 Active not recruiting

590 enrolled 12 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04285567 2026-03-03

CRISTALLO

Phase 3 Completed

166 enrolled 27 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02970318 2026-02-06

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Phase 3 Active not recruiting

310 enrolled 18 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03834688 2025-08-11

PrE0405

Phase 2 Completed

33 enrolled 15 charts

Lymphoma, Mantle-Cell

NCT03739619 2025-08-06

Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1/2 Completed

3 enrolled 10 charts

Hodgkin Disease

NCT03872180 2025-08-06

Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Phase 2 Active not recruiting

23 enrolled 15 charts

Lymphoma, Mantle-Cell

NCT02763319 2025-07-17

B-MIND

Phase 2/3 Completed

453 enrolled 29 charts

Lymphoma, Large B-Cell, Diffuse

NCT01776840 2025-07-08

A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 3 Completed

523 enrolled 28 charts

Lymphoma, Mantle-Cell

NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Phase 2 Active not recruiting

69 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

NCT01974440 2025-05-25

SELENE

Phase 3 Completed

403 enrolled 23 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT04217317 2025-05-02

CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Phase 2 Terminated

6 enrolled 13 charts

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell

NCT01458366 2025-04-30

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

Phase 1/2 Completed

38 enrolled 17 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT02224729 2025-04-30

Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Completed

24 enrolled 13 charts

Multiple Myeloma

NCT04666038 2025-04-20

BRUIN CLL-321

Phase 3 Active not recruiting

238 enrolled 17 charts 3 FDA

LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT01415752 2025-04-08

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

Phase 2 Active not recruiting

373 enrolled 14 charts

Lymphoma, Lymphoma, Mantle-Cell

NCT01437709 2025-02-28

Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

Phase 2 Completed

30 enrolled 15 charts

Lymphoma, Mantle-Cell

NCT02927769 2025-02-10

CheckMate 744

Phase 2 Completed

72 enrolled 24 charts

Hodgkin Disease

NCT03187223 2025-01-30

BEB-2

Phase 2 Completed

120 enrolled 11 charts

Multiple Myeloma

NCT02626455 2024-12-11

CHRONOS-4

Phase 3 Terminated

551 enrolled 32 charts

Lymphoma, Non-Hodgkin

NCT04745832 2024-11-04

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Phase 3 Terminated

82 enrolled 11 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT03311126 2024-10-24

Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Phase 2 Terminated

21 enrolled 17 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT02002598 2024-09-19

Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma

Phase 1/2 Terminated

23 enrolled 13 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Phase 3 Completed

120 enrolled 14 charts

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02148913 2024-07-26

Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma

Phase 1 Completed

18 enrolled 10 charts

Multiple Myeloma

NCT01664910 2024-07-23

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Phase 1/2 Completed

27 enrolled 12 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT01716806 2024-06-11

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Phase 2 Completed

131 enrolled 28 charts

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Peripheral

NCT02348216 2024-06-04

ZUMA-1

Phase 1/2 Completed

307 enrolled 41 charts

Lymphoma, Large B-Cell, Diffuse

NCT01754402 2024-02-20

Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Phase 1/2 Unknown

56 enrolled 12 charts

Multiple Myeloma

NCT02733042 2023-11-18

FUSION NHL 001

Phase 1/2 Completed

106 enrolled 48 charts

LymphoidOther hematologic neoplasm

Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02005471 2023-10-17

MURANO

Phase 3 Completed

389 enrolled 35 charts 4 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01177683 2023-10-06

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Phase 1/2 Terminated

32 enrolled 18 charts

Multiple Myeloma

NCT01216683 2023-06-29

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Phase 2 Completed

289 enrolled 34 charts

Lymphoma, Lymphoma, Follicular

NCT01754857 2023-06-27

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

Phase 2 Completed

36 enrolled 11 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01596621 2023-05-26

A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment

Phase 3 Completed

102 enrolled 21 charts

Lymphoma, Non-Hodgkin

NCT04236141 2023-03-03

A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

Phase 3 Terminated

42 enrolled 28 charts

Lymphoma, Large B-Cell, Diffuse

NCT02257242 2023-02-09

BRiM

Phase 1 Completed

11 enrolled 20 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02853370 2023-02-01

Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma

Phase 2 Completed

78 enrolled 20 charts

Lymphoma, B-Cell, Marginal Zone

NCT02257567 2022-11-14

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Phase 1/2 Completed

331 enrolled 81 charts 2 FDA

Lymphoma

NCT01332968 2022-08-11

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Phase 3 Completed

1,401 enrolled 40 charts

Lymphoma, Non-Hodgkin

NCT04155840 2022-04-11

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2 Terminated

1 enrolled 6 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02954406 2022-02-18

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

Phase 1 Terminated

43 enrolled 27 charts

Lymphoma, Non-Hodgkin

NCT02424851 2022-01-27

OPTIMAL

Phase 2 Completed

31 enrolled 13 charts

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

NCT01535924 2021-11-19

Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase 1/2 Completed

26 enrolled 13 charts

Hodgkin Disease, Recurrence

NCT01412879 2021-10-29

S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

Phase 2 Completed

53 enrolled 10 charts

Lymphoma, Lymphoma, Mantle-Cell

NCT01188681 2021-06-10

Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia

Phase 1/2 Completed

79 enrolled 13 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02596971 2021-05-24

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Completed

91 enrolled 27 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse